Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL9998724 | 0.98 | SMN1; SMN2 (0.51) | SMN1; SMN2CYP2D6CYP2C19TSHRMMP1 | |
| SCHEMBL20580387 | 0.94 | SMN1; SMN2 (0.49) | SMN1; SMN2CYP2D6CYP2C19TSHRMMP1 | |
| SCHEMBL12116102 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2CYP2D6CYP2C19TSHRALDH1A1 | |
| SCHEMBL15148250 | 0.85 | SMN1; SMN2 (0.49) | SMN1; SMN2CYP2D6CYP2C19TSHRALDH1A1 | |
| SCHEMBL22361561 | 0.85 | SMN1; SMN2 (0.49) | SMN1; SMN2CYP2D6CYP2C19TSHRALDH1A1 | |
| SCHEMBL15148251 | 0.85 | CYP2C19 (0.45) | SMN1; SMN2CYP2D6CYP2C19MMP1MMP8 | |
| SCHEMBL19364750 | 0.85 | CYP2D6 (0.45) | SMN1; SMN2CYP2D6CYP2C19MMP1MMP8 | |
| SCHEMBL19343055 | 0.82 | SMN1; SMN2 (0.46) | SMN1; SMN2CYP2D6CYP2C19MMP1MMP8 | |
| SCHEMBL19355185 | 0.82 | CYP2D6 (0.42) | SMN1; SMN2CYP2D6CYP2C19MMP1MMP8 | |
| SCHEMBL19343052 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2CYP2C19TSHRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-09-14 | — | — | US | disclosed |
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170301950-A1 | SOLID ELECTROLYTE COMPOSITION, ELECTRODE SHEET FOR BATTERY USING THE SAME, ALL SOLID STATE SECONDARY BATTERY, AND METHOD FOR MANUFACTURING ELECTRODE SHEET FOR BATTERY AND ALL SOLID STATE SECONDARY BATTERY | FUJIFILM CORPORATION (JP) | 2017-10-19 | — | — | US | disclosed |
| US-20170301950-A1 | SOLID ELECTROLYTE COMPOSITION, ELECTRODE SHEET FOR BATTERY USING THE SAME, ALL SOLID STATE SECONDARY BATTERY, AND METHOD FOR MANUFACTURING ELECTRODE SHEET FOR BATTERY AND ALL SOLID STATE SECONDARY BATTERY | FUJIFILM CORPORATION (JP) | 2017-10-19 | — | — | US | disclosed |
| US-20170189477-A1 | Methods and Compositions of P27KIP1 Transcriptional Modulators | NIH-DEITR | 2017-07-06 | — | — | US | disclosed |
| US-20170189477-A1 | Methods and Compositions of P27KIP1 Transcriptional Modulators | NIH-DEITR | 2017-07-06 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-9572815-B2 | Methods and compositions of p27KIP1 transcriptional modulators | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160030445-A1 | METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTIONAL MODULATORS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2016-02-04 | — | — | US | disclosed |
| US-8507522-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20090098130-A1 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2009-04-16 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| CN-101237886-A | Compositions for producing weight loss | OREXIGEN THERAPEUTICS INC (US) | 2008-08-06 | — | — | CN | disclosed |
| US-20080166364-A1 | Conjugated to antibody; thrombospondin receptor targeting | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2008-07-10 | — | — | US | disclosed |
| US-20080152660-A1 | Anti-Angiogenic Compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2008-06-26 | — | — | US | disclosed |
| EP-1907005-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | Orexigen Therapeutics, Inc. (US) | 2008-04-09 | — | — | EP | disclosed |
| US-20080045516-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045516-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20070117827-A1 | Compositions for affecting weight loss | U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2007-05-24 | — | — | US | disclosed |
| WO-2007016108-A1 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | OREXIGEN THERAPEUTICS, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | SMN1; SMN2 3741/4885CYP2D6 497/4885CYP2C19 180/4885 |
| US-20070117827-A1 | Compositions for affecting weight loss | MC4R, MC3R, MC5R | SMN1; SMN2 784/4885CYP2D6 867/4885CYP2C19 1229/4885 |
| US-10017499-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | SMN1; SMN2 3511/4885CYP2D6 365/4885CYP2C19 105/4885 |
| US-20080166364-A1 | Conjugated to antibody; thrombospondin receptor targeting | TEK, KDR, FLT4 | SMN1; SMN2 2507/4885CYP2D6 4794/4885CYP2C19 4810/4885 |
| US-20090098130-A1 | GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS | GLP1R, GIPR, GCGR | SMN1; SMN2 3888/4885CYP2D6 4658/4885CYP2C19 4670/4885 |
| US-20230286970-A1 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | HDAC6, HDAC1, HDAC3 | SMN1; SMN2 2068/4885CYP2D6 2976/4885CYP2C19 3803/4885 |
| US-20170189477-A1 | Methods and Compositions of P27KIP1 Transcriptional Modulators | WNT1, CTNNB1, CTNNBL1 | SMN1; SMN2 4085/4885CYP2D6 4033/4885CYP2C19 4723/4885 |
| US-20160030445-A1 | METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTIONAL MODULATORS | WNT1, CTNNB1, CTNNBL1 | SMN1; SMN2 4190/4885CYP2D6 4131/4885CYP2C19 4740/4885 |
| US-20080045516-A1 | Viral Polymerase Inhibitors | POLR2A, POLR2H, POLR2E | SMN1; SMN2 4053/4885CYP2D6 465/4885CYP2C19 712/4885 |
| US-20080152660-A1 | Anti-Angiogenic Compounds | VEGFA, FLT4, KDR | SMN1; SMN2 3528/4885CYP2D6 4784/4885CYP2C19 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.